Skip to content

Topiramate’s effectiveness on weight reduction in overweight/obese persons with Schizophrenia

Topiramate’s effectiveness on weight reduction in overweight/obese persons with Schizophrenia: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2017/003
Enrollment
Unknown
Registered
2017-02-20
Start date
2017-03-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, Obesity, Overweight

Interventions

The study will be carried out at the outpatient psychiatry clinic of the Colombo North Teaching Hospital, Ragama, Sri Lanka. Consenting participants meeting inclusion criteria will be allocated into

Sponsors

Department of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of schizophrenia (International Classification of Diseases (ICD), 10th edition) 2. Age 18 years and above 3. Capacity to give informed consent (as determined by assessment of an external psychiatrist) 4. Body Mass Index above the cut-off for Asians, which is 23 kg/m2 by the World Health Organization

Exclusion criteria

Exclusion criteria: 1. Diabetes mellitus 2. Hypertension 3. Dyslipidaemia 4. Patients on other weight reducing agents 5. Patients with a significant loss of appetite leading to loss of more than 10% of body weight over a period of six months 6. Patients with difficulty in swallowing 7. Pregnant and lactating females

Design outcomes

Primary

MeasureTime frame
Reduction in body weight [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ] Reduction in waist circumference [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ] Reduction in skin fold thickness [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ]

Secondary

MeasureTime frame
A potential change in psychiatric symptoms as measured by the brief psychiatric rating scale (BPRS) [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ]

Countries

Sri Lanka

Contacts

Public ContactMiyuru Chandradasa

Lecturer in Psychiatry

miyuruc@kln.ac.lk+94710443352

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026